Earlier Heart Failure Treatment | NICE Guidelines
- Thousands of individuals in England with early-stage chronic heart failure could see improved outcomes thanks to updated draft guidance from the National Institute for Health and Care Excellence...
- The guidance, an update to NICE’s 2018 clinical recommendations, specifically advises earlier treatment for heart failure with reduced ejection fraction (HFrEF).
- The four cornerstones of HFrEF treatment include angiotensin-converting enzyme inhibitors (ACEI), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.
England’s chronic heart failure patients may soon benefit from updated NICE guidelines, with the chief takeaway being: earlier access to crucial drug therapies. This notable shift recommends quicker use of combination therapies, including SGLT2 inhibitors, potentially preventing thousands of deaths adn hospitalizations annually. Beyond medication, the updated advice covers diagnosis and monitoring, emphasizing iron deficiency and anemia assessments. The National Institute for Health and Care Excellence wants to widen patient access to effective treatments.News Directory 3 reports on evolving clinical practices and what these changes mean for the close to one million people in the UK living with heart failure. Discover what’s next as the guidance enters public consultation.
NICE Recommends Earlier Treatment for Chronic Heart Failure
Updated june 11, 2025
Thousands of individuals in England with early-stage chronic heart failure could see improved outcomes thanks to updated draft guidance from the National Institute for Health and Care Excellence (NICE). The new recommendations focus on earlier access to effective drug therapies for heart failure patients.
The guidance, an update to NICE’s 2018 clinical recommendations, specifically advises earlier treatment for heart failure with reduced ejection fraction (HFrEF). NICE noted that clinical practice is evolving, and medications should be offered up to a year sooner in the treatment process. This shift in approach could potentially prevent 3,000 deaths and 5,500 hospital admissions annually in England, according to NICE estimates.
The four cornerstones of HFrEF treatment include angiotensin-converting enzyme inhibitors (ACEI), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. NICE now suggests these drugs be prescribed earlier, without requiring the optimization of one medication’s dose before introducing another. SGLT2 inhibitors, such as empagliflozin and dapagliflozin, should be considered at the beginning of treatment, rather than after other medications have been fully adjusted—a process that can take over a year. NICE also advises that angiotensin receptor-neprilysin inhibitors (ARNI) be offered if a patient cannot tolerate an ACEI, instead of only to those stabilized on ACEI or angiotensin receptor blockers (ARBs). Both SGLT2 inhibitors and ARNI could be initiated by general practitioners with specialist advice, potentially accelerating patient access to crucial treatments for chronic heart failure.
“We’ve been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments,” said Eric Power, deputy director in NICE’s center for guidelines.He added that the updated approach could reduce emergency hospital admissions and improve the quality of life for individuals managing heart failure.
NICE has also updated its guidance on diagnosis and monitoring, particularly concerning iron deficiency and anemia in HFrEF patients. Clinicians should assess iron status and check for anemia using transferrin saturation (TSAT), serum ferritin, and hemoglobin. Intravenous iron should be considered for patients with hemoglobin levels below 150 g/L and TSAT below 20% or ferritin below 100 ng/mL.If iron deficiency anemia is identified,clinicians should investigate potential causes beyond heart failure.
Additionally, NICE advises clinicians to consider that an N-terminal pro B-type natriuretic peptide level below 400 ng/L (47 pmol/L) in an untreated individual makes a heart failure diagnosis less likely. serum natriuretic peptide levels do not differentiate between heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, and hfref. Factors such as obesity,African or African-Caribbean ethnicity,or treatment with diuretics,ACEIs,ARNIs,ARBs,beta-blockers,or MRAs can reduce serum natriuretic peptide levels. Elevated natriuretic peptide levels may also stem from non-cardiac conditions like chronic obstructive pulmonary disease, diabetes, sepsis, and liver or kidney disease.
Nearly 1 million peopel in the United Kingdom are living with heart failure, with approximately 200,000 new diagnoses each year. The average age at diagnosis is 76. Increased life expectancy and rising obesity rates are contributing to the growing incidence and prevalence of this condition.
What’s next
The draft guidance is now open for public consultation, with final recommendations expected later this year. These changes aim to improve the management of chronic heart failure and enhance patient outcomes.